FMR LLC Reports 9.63% Stake in Regeneron Pharma

TL;DR

**FMR LLC still owns 9.63% of Regeneron, a strong institutional vote of confidence.**

AI Summary

FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Regeneron Pharmaceuticals Inc. As of December 31, 2023, they collectively beneficially own 10,317,407 shares of common stock, representing 9.630% of the company. This is an amendment (Amendment No. 5) to a previous filing, indicating a slight adjustment in their reported holdings. This matters to investors because FMR LLC is a significant institutional holder, and changes in their reported stake can signal their ongoing confidence (or lack thereof) in Regeneron's future prospects.

Why It Matters

This filing shows that a major institutional investor, FMR LLC, maintains a substantial stake in Regeneron, which can be seen as a vote of confidence in the company's long-term value.

Risk Assessment

Risk Level: low — This filing indicates a stable, significant institutional ownership, which generally reduces volatility and provides a degree of stability.

Analyst Insight

Investors should note that a major institutional holder like FMR LLC maintains a substantial position, suggesting continued confidence in Regeneron. While not a direct buy signal, it provides a positive data point for long-term holders.

Key Numbers

• 10,317,407 — Shares Beneficially Owned (Represents the total common stock shares of Regeneron Pharmaceuticals Inc. held by FMR LLC and Abigail P. Johnson.)
• 9.630% — Percent of Class (Indicates the proportion of Regeneron's common stock owned by FMR LLC and Abigail P. Johnson, showing their significant stake.)

Key Players & Entities

• FMR LLC (company) — reporting person and parent holding company
• Abigail P. Johnson (person) — reporting person, principal owner of FMR LLC
• REGENERON PHARMACEUTICALS, INC. (company) — subject company, issuer of the securities
• 10,317,407 (dollar_amount) — total shares beneficially owned by FMR LLC and Abigail P. Johnson
• 9.630% (dollar_amount) — percentage of class beneficially owned

Forward-Looking Statements

• FMR LLC will maintain a significant, albeit potentially fluctuating, stake in Regeneron Pharmaceuticals Inc. over the next year. (FMR LLC) — high confidence, target: 2025-02-09

FAQ

From the Filing

0000315066-24-001496.txt : 20240209 0000315066-24-001496.hdr.sgml : 20240209 20240209094931 ACCESSION NUMBER: 0000315066-24-001496 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240209 DATE AS OF CHANGE: 20240209 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-41938 FILM NUMBER: 24612062 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: FMR LLC CENTRAL INDEX KEY: 0000315066 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] ORGANIZATION NAME: IRS NUMBER: 043532603 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6175706339 MAIL ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: FMR CORP DATE OF NAME CHANGE: 19920717 SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.5 REGENERON PHARMACEUTICALS INC COMMON STOCK Cusip #75886F107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #75886F107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 9,968,323 Item 6: 0 Item 7: 10,317,407 Item 8: 0 Item 9: 10,317,407 Item 11: 9.630% Item 12: HC Cusip #75886F107 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 10,317,407 Item 8: 0 Item 9: 10,317,407 Item 11: 9.630% Item 12: IN Item 1(a). Name of Issuer: REGENERON PHARMACEUTICALS INC Item 1(b). Address of Issuer's Principal Executive Offices: 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 75886F107 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 10,317,407 (b) Percent of Class: 9.630% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 10,317,407 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of REGENERON PHARMACEUTICALS INC. No one other person's interest in the COMMON STOCK of REGENERON PHARMACEUTICALS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item